Amylyx Pharmaceuticals, Inc. (AMLX) Stock
AMLX has an Alpha Score of 35 out of 100 (weak), computed on Nov 6, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 1 trade in AMLX since 2022: 1 purchase and 0 sales, most recently Christopher L. Jacobs (purchase, Oct 12, 2022). 2 of the hedge funds AlphaScala tracks reported AMLX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $3.21M. Company insiders reported 0 open-market buys and 11 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
What is AMLX's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Amylyx Pharmaceuticals, Inc. (AMLX)?
Most recent: Christopher L. Jacobs (purchase, Oct 12, 2022); records start Oct 12, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-10-12 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all AMLX political trades →Which hedge funds own AMLX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 179K | $3.21M | -57% |
| D.E. Shaw David Shaw | 174K | $3.13M | +135% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Amylyx Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Milne George M Jr | Director | SELL | 30.0K | $831K |
| Sep 10, 26 | Klee Justin B. | Co-Chief Executive Officer | SELL | 29.0K | $933K |
| Sep 10, 26 | Klee Justin B. | Co-Chief Executive Officer | SELL | 1.4K | $48K |
| Sep 10, 26 | Cohen Joshua B | Co-Chief Executive Officer | SELL | 29.5K | $950K |
| Sep 10, 26 | Cohen Joshua B | Co-Chief Executive Officer | SELL | 919 | $30K |
| Sep 10, 26 | Mazzariello Gina | Chief Legal Officer | SELL | 9.5K | $309K |
| Sep 10, 26 | Mazzariello Gina | Chief Legal Officer | SELL | 11 | $367 |
| Sep 10, 26 | Frates James M | Chief Financial Officer | SELL | 9.8K | $315K |
| Sep 10, 26 | Frates James M | Chief Financial Officer | SELL | 1.0K | $35K |
| Sep 10, 26 | Bedrosian Camille L | Chief Medical Officer | SELL | 7.9K | $256K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are AMLX's key statistics?
Key statistics as of Nov 6, 2026
How does AMLX's valuation compare with the Healthcare sector?
| Metric | AMLX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -94.56% | 4.11% | 160 |
| Return on equity | -52.92% | 5.18% | 180 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
AMLX price chart
Powered by TradingViewWhat does Amylyx Pharmaceuticals, Inc. do?
Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions. The company focuses on advancing its pipeline, including avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol under investigation for Wolfram syndrome; AMX0114 in Phase 1 for amyotrophic lateral sclerosis; and AMX0318, a long-acting GLP-1 receptor antagonist candidate for post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals targets unmet needs in conditions like progressive supranuclear palsy, ALS, and endocrine disorders through clinical trials emphasizing safety, tolerability, and efficacy data. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company operates globally with subsidiaries supporting its research and development efforts in these critical therapeutic areas.